- main use is for the prophylaxis of hemorrhagic disease of the newborn
- vitamin K is required for the synthesis of the 4 known vitamin K - dependent coagulation factors, II (prothrombin), VII (proconvertin), IX (plasma thromboplastin) and X (Stuart factor), as well as protein C (an important inhibitor of coagulation)
- flushing, weakness, cramping pains, swelling at injection site
- following large doses, severe hemolytic anemia, with indirect hyperbilirubinemia
|Birth Weight < 1500 g: 0.5 mg IM once|
Birth Weight > 1500 g: 1.0 mg IM once
- dosage is given only once, on admission, unless ordered otherwise
- mothers who take drugs that impair vitamin K metabolism (eg. anticonvulsants, rifampin) should be given vitamin K1 20 mg/d orally, for at least 2 weeks before the expected time of delivery
- infants at high risk for secondary late hemorrhagic disease due to cystic fibrosis, chronic diarrhea etc should be given vitamin K1 50 to 100 ug/day orally or 1 mg IM once a month
- 1 mg/0.5 mL ampoule
- McEvoy G K (ed): AHFS Drug Information, American Society of Hospital Pharmacists, 1991.
- Fetus and Newborn Committee, Canadian Pediatric Society: The use of Vitamin K in the perinatal period, CMAJ 1988; 139:127-130.